Outpatient Surgery Magazine

Marking Madness - April 2013 - Subscribe

Outpatient Surgery Magazine, providing current information on Surgical Services, Surgical Facility Administration, Outpatient Surgery News and Trends, OR Excellence and more.

Issue link: http://outpatientsurgery.uberflip.com/i/122240

Contents of this Issue


Page 120 of 157

OSM560-April_DIGITAL_Layout 1 4/5/13 2:31 PM Page 121 www.dantrium.com *JHP's Dantrium® IV has a 36 month shelf life at manufacturing point. There is always some lag period between manufacturing date and when the product ships to the end user, which varies based on when the order is placed. Safety Information Management of Malignant Hyperthermia (MH) crises requires various supportive measures individualized for the patient's condition. Administration of Dantrium® IV is one component of therapy and should not be considered a substitute for these measures. Even when properly treated, an MH crisis can result in death. Adverse events with Dantrium® IV include loss of grip strength, weakness in the legs, drowsiness, and dizziness, thrombophlebitis, and tissue necrosis/injection site reactions secondary to extravasation. There have been rare reports of pulmonary edema, urticaria and erythema. Symptomatic hepatitis (fatal and non-fatal) has been reported at various dose levels of the drug. Fatal and non-fatal liver disorders of an idiosyncratic or hypersensitivity type may occur with Dantrium® therapy. In case of overdose, symptoms include, but are not limited to, muscular weakness, lethargy, coma, vomiting, diarrhea, and crystalluria. For acute overdosage, general supportive measures should be employed. Please visit www.dantrium.com for additional product information. For full prescribing information, please see reverse. DAN3000-313 A P R I L 2 013 | O U T PAT I E N T S U R G E R Y M A G A Z I N E | 1 2 1

Articles in this issue

Links on this page

Archives of this issue

view archives of Outpatient Surgery Magazine - Marking Madness - April 2013 - Subscribe